Next-generation sequencing–based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse-Reference-Cited by-同舟云学术

Next-generation sequencing–based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse

Published:2018-10-11 Issue:15 Volume:132 Page:1604-1613
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kim TaeHyung¹²,Moon Joon Ho³^ORCID,Ahn Jae-Sook⁴⁵,Kim Yeo-Kyeoung⁴⁵,Lee Seung-Shin⁴⁵,Ahn Seo-Yeon⁴⁵,Jung Sung-Hoon⁴⁵,Yang Deok-Hwan⁴⁵,Lee Je-Jung⁴⁵,Choi Seung Hyun⁵,Lee Ja-yeon⁵,Tyndel Marc S.²⁶,Shin Myung-Geun⁷,Lee Yoo Jin³,Sohn Sang Kyun³,Park Seong-Kyu⁸,Zhang Zhaolei¹²⁹,Kim Hyeoung-Joon⁴⁵,Kim Dennis Dong Hwan¹⁰

Affiliation:

1. Department of Computer Science and

2. The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada;

3. Department of Hematology-Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea;

4. Department of Hematology-Oncology and

5. Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea;

6. The Edward S. Rogers Sr. Department of Electrical and Computer Engineering, University of Toronto, Toronto, ON, Canada;

7. Department of Laboratory Medicine, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea;

8. Department of Hematology-Oncology, Soon Chun Hyang University Hospital, Bucheon, Republic of Korea; and

9. Department of Molecular Genetics and

10. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

Abstract

Key Points Higher allelic burden at day 21 of post-HCT is associated with higher risk of relapse and mortality. Longitudinal tracking of AML patients receiving HCT is feasible and provides clinically relevant information.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/132/15/1604/1407126/blood848028.pdf

Reference42 articles.

1. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia [published correction appears in N Engl J Med. 2013;369(1):98];Ley;N Engl J Med,2013

2. Genomic classification and prognosis in acute myeloid leukemia;Papaemmanuil;N Engl J Med,2016

3. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials;Grimwade;Blood,2010

4. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations;Döhner;Blood,2005

5. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia;Schlenk;N Engl J Med,2008

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation;Blood;2024-07-18

2. Clonal Hematopoiesis-Associated Gene Mutations Affect Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation in AML Patients;Annals of Transplantation;2024-05-28

3. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study;Journal of Translational Medicine;2024-04-30

4. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis;Blood Advances;2024-04-23

5. Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia;Scientific Reports;2024-04-12